Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9733)	12/11/2003 4:27:23 PM
From: Sam Citron	Respond to of 52153

Some eyebrows will always go up. I have noticed that almost everybody has a China office or two, but almost nobody is in India. I wonder why? IIT is moving into biotech. I expect a big push to Indian CRO soon.

To: Biomaven who wrote (9733)	12/12/2003 1:47:38 AM
From: Sam Citron	Read Replies (2) \| Respond to of 52153

Peter, I may have to revise downward my previous estimate that offshore CRO may soon take off the way that BPO has. It appears that by the time a drug enters clinical trial stage, so much has been spent and so much is at stake that pharma may be loath to send it off to India or China to save a few million dollars. Pharma will want maximum control and not risk perception that FDA may look askance at data from a nonlocal population. I understand that Japan actually has a law that requires drugs sold in Japan to be clinically tested on Japanese nationals. Whether that is merely protectionism or sound scientific precaution, I do not know. Sam